Boshqa

Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis

Giovanni SotgiuClinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy [email protected]Simon TiberiDivision of Infection, Barts Health NHS Trust, London, UKLia D’AmbrosioFondazione S. Maugeri, IRCCS, Care and Research Institute, Tradate, ItalyRosella CentisFondazione S. Maugeri, IRCCS, Care and Research Institute, Tradate, ItalyJan‐Willem C. AlffenaarDept of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The NetherlandsJosé A. CamineroMDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease (The Union), Paris, FranceMarcos Abdo ArbexHospital Nestor Goulart Reis, Sao Paulo State Secretary of Health, Sao Paulo, BrazilValentina Alarcon GuizadoNational Tuberculosis Control Programme, Ministry of Health, Lima, PeruAlena AleksaEducational Institution "Grodno State Medical University", Grodno, BelarusSimone DoreClinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, ItalyMina GagaMDR-TB Unit, Athens Chest Hospital Sotira, National Referral Centre for Mycobacteria, Athens, GreeceGina GualanoRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases 'L. Spallanzani' IRCCS, Rome, ItalyHeinke KunstDept of Respiratory Medicine, Queen Mary University, London, UKMarie-Christine PayenDivision of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, BelgiumAurora Jazmín Roby AriasAlena SkrahinaRepublican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, BelarusIvan SolovičNational Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Catholic University Ruzomberok, Ružomberok, SlovakiaGiorgia SulisUniversity Dept of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV Co-infection and for TB Elimination - University of Brescia and Brescia Spedali Civili General Hospital, Brescia, ItalyMarina TadoliniUnit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, ItalyAlimuddin ZumlaDivision of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UKGiovanni Battista MiglioriFondazione S. Maugeri, IRCCS, Care and Research Institute, Tradate, Italy

2016en

ABI

Annotatsiya

Multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are growing clinical and public health concerns, with an estimated worldwide incidence and mortality of 480 000 and 190 000 cases, respectively (2014) [1]. The World Health Organization (WHO) End TB Strategy reiterates the MDR-/XDR-TB threat and the solutions to control the epidemic [2]. Unfortunately, large proportions of patients with resistant TB do not have access to adequate diagnostics and treatment yet, while treatment success rates remain suboptimal (as demonstrated in the largest retrospective cohort of MDR-TB patients, i.e. , TB caused by Mycobacterium tuberculosis isolates resistant to at least isoniazid and rifampicin) and decrease further with resistance patterns beyond XDR-TB [3]. Evaluation of drug resistances is needed to identify candidates for the shorter regimen in MDR-TB hot spots <http://ow.ly/wZV33022VXt> The authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions and policies of their institutions. All authors contributed to the conception of the study, data analysis, interpretation of the results, drafting of the manuscript and approval of the final version. Members of the International Carbapenem Study Group: M. Abdo Arbex (Brazil), O.W. Akkerman (The Netherlands), E. Alarcon Arrascue (Peru), V. Alarcon Guizado (Peru), A. Aleksa (Belarus), J.W. Alffenaar (The Netherlands), J. Artsukevich (Belarus), V. Avchynka (Belarus), J.A. Caminero (Spain), R. Centis (Italy), L. D'Ambrosio (Italy), S. De Lorenzo (Italy), S. Dore (Italy), M. Gaga (Greece), G. Gualano (Italy), A.J. Roby Arias (Ecuador), E.H. Bonini (Brazil), F.A. Chong Marín (Ecuador), G. de Vries (The Netherlands), S. Dore (Italy), H. Kunst (UK), A. Matteelli (Italy), G.B. Migliori (Italy), C. Moschos (Greece), F. Palmieri (Italy), A. Papavasileiou (Greece), M.C. Payen (Belgium), A. Piana (Italy), A. Scardigli (France), A. Skrahina (Belarus), I. Solovic (Slovakia), G. Sotgiu (Italy), A. Spanevello (Italy), G. Sulis (Italy), M. Tadolini (Italy), S. Tiberi (UK), D. Vargas Vasquez (Peru), P. Viggiani (Italy), V. White (UK), A. Zumla (UK).

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1183/13993003.01249-2016

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar